Tracer library / [68Ga]BCY18469

[68Ga]BCY18469

Also written as [Ga-68]Ga-BCY18469

Radionuclide: Ga-68 t½ 67.71 min
Modality: PET
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: EphA2-targeting bicyclic peptide (Bicycle®)
Target / mechanism: EphA2 (erythropoietin-producing hepatocellular receptor A2) PMID 39239524
Clinical application: Tumors overexpressing EphA2, proposed for radiotheranostic applications PMID 39239524
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	—	≥98%	BCY18469	39239524 2024 Theranostics Radiolabeling with 68Ga was performed by mixing equal parts (40 - 150 µL) of 1.0 M HEPES buffer

Need this precursor?We can point you to suppliers for [68Ga]BCY18469, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39239524. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Ga-68 is a positron emitter used only for PET imaging. Linked articles: PMID 39239524. Stage set/updated at stage 39 from PMID 39239524: 'This study presents the development and comprehensive in vitro and in vivo preclinical evaluation of BCY18469, a novel EphA2-targeting bicyclic peptide-based radiotheranostic agent.'.